Assessment of Ischemia Modified Albumin as a Marker of Oxidative Stress in Chronic Kidney Disease

Basit Öğe Kaydı
dc.contributor.authorOzkurt, Sultan
dc.contributor.authorOzcan, Oguzhan
dc.contributor.authorDogan, Ibrahim
dc.date.accessioned2024-09-18T21:06:40Z
dc.date.available2024-09-18T21:06:40Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractIncreased oxidative stress (OS) in chronic kidney disease (CKD), and particularly in those undergoing hemodialysis (HD), is widely recognized. We aimed to evaluate ischemia modified albumin (IMA) as a marker of OS in CKD patients who are not yet on HD compared to chronic HD patients. A cross-sectional study was conducted in Hitit University, Corum, Turkey in 2015. In this study, 39 chronic HD and 36 CKD patients in stage 3-4 were included, as well as 34 healthy individuals as a control group. IMA levels in HD patients (before and after HD session), stage 3-4 CKD patients and control group were evaluated using the ELISA method. Pre-HD and post-HD albumin levels were measured and albumin-adjusted IMA (aIMA) levels were calculated. IMA and aIMA levels were higher in chronic HD and CKD patients who are not yet on HD, compared to healthy individuals (IMA, 179.76 +/- 60.46, 209.67 +/-& nbsp; 69.84, 67.41 +/- 32.22, P < 0.001, respectively, aIMA, 186.22 +/-& nbsp; 64.84, 212.96 +/-& nbsp; 72.84, 68.80 +/- ; 34.42, P < 0.001, respectively). Likewise, IMA and aIMA levels in post-HD patients were higher than pre-HD levels (IMA, 294.62 +/- 66.64, 179.76 +/-& nbsp; 60.46, P < 0.001, respectively, aIMA, 298.31 +/-& nbsp; 70.93, 186.22 & PLUSMN; 64.83, P < 0.001). Linear regression analysis identified glomerular filtration rate as the most effective factor on IMA (P < 0.001). CKD is associated with increased OS and the HD procedure itself also contributes to the increase in OS. IMA may serve as a feasible biomarker for determination of OS.& nbsp;en_US
dc.identifier.doi10.4103/1319-2442.338273
dc.identifier.endpage1012en_US
dc.identifier.issn1319-2442
dc.identifier.issn2320-3838
dc.identifier.issue4en_US
dc.identifier.pmid35229799en_US
dc.identifier.scopus2-s2.0-85125680483en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1006en_US
dc.identifier.urihttps://doi.org/10.4103/1319-2442.338273
dc.identifier.urihttps://hdl.handle.net/20.500.12483/13755
dc.identifier.volume32en_US
dc.identifier.wosWOS:000795907600014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofSaudi Journal of Kidney Diseases and Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMyocardial-Ischemiaen_US
dc.subjectHemodialysisen_US
dc.subjectBiomarkersen_US
dc.subjectBindingen_US
dc.subjectProteinen_US
dc.subjectAssayen_US
dc.titleAssessment of Ischemia Modified Albumin as a Marker of Oxidative Stress in Chronic Kidney Diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu